JP2021516240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021516240A5 JP2021516240A5 JP2020546499A JP2020546499A JP2021516240A5 JP 2021516240 A5 JP2021516240 A5 JP 2021516240A5 JP 2020546499 A JP2020546499 A JP 2020546499A JP 2020546499 A JP2020546499 A JP 2020546499A JP 2021516240 A5 JP2021516240 A5 JP 2021516240A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- halo
- hydrogen
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 77
- 229910052739 hydrogen Inorganic materials 0.000 claims 42
- 239000001257 hydrogen Substances 0.000 claims 42
- 125000003545 alkoxy group Chemical group 0.000 claims 40
- 125000005843 halogen group Chemical group 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 20
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 15
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 12
- 125000001188 haloalkyl group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 7
- 206010019280 Heart failures Diseases 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 229910052698 phosphorus Inorganic materials 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000004438 haloalkoxy group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 229910052717 sulfur Chemical group 0.000 claims 4
- 239000011593 sulfur Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- -1 R 1 R 2 N Chemical group 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 1
- 208000008253 Systolic Heart Failure Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001269 cardiogenic effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- JKIIGSYRQKRWIC-UHFFFAOYSA-N CS(Nc(cccc1)c1-c(ccc(N(CCC1NC(Nc(c(F)c2)ccc2Cl)=O)C1=O)c1F)c1F)(=O)=O Chemical compound CS(Nc(cccc1)c1-c(ccc(N(CCC1NC(Nc(c(F)c2)ccc2Cl)=O)C1=O)c1F)c1F)(=O)=O JKIIGSYRQKRWIC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862638556P | 2018-03-05 | 2018-03-05 | |
| US62/638,556 | 2018-03-05 | ||
| PCT/US2019/020493 WO2019173182A1 (en) | 2018-03-05 | 2019-03-04 | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516240A JP2021516240A (ja) | 2021-07-01 |
| JP2021516240A5 true JP2021516240A5 (enExample) | 2021-08-12 |
| JP7155276B2 JP7155276B2 (ja) | 2022-10-18 |
Family
ID=65812419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546499A Active JP7155276B2 (ja) | 2018-03-05 | 2019-03-04 | フェニルピロリジノンホルミルペプチド２受容体アゴニスト |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10676431B2 (enExample) |
| EP (2) | EP3762380B1 (enExample) |
| JP (1) | JP7155276B2 (enExample) |
| KR (1) | KR102803660B1 (enExample) |
| CN (1) | CN111868052B (enExample) |
| AR (1) | AR114429A1 (enExample) |
| AU (1) | AU2019232704B2 (enExample) |
| BR (1) | BR112020017744A2 (enExample) |
| CA (1) | CA3092927A1 (enExample) |
| CL (1) | CL2020002224A1 (enExample) |
| CY (1) | CY1124985T1 (enExample) |
| DK (1) | DK3762380T3 (enExample) |
| EA (1) | EA202092094A1 (enExample) |
| ES (1) | ES2904483T3 (enExample) |
| HR (1) | HRP20220118T1 (enExample) |
| HU (1) | HUE058044T2 (enExample) |
| IL (1) | IL277044B2 (enExample) |
| LT (1) | LT3762380T (enExample) |
| MX (1) | MX2020009000A (enExample) |
| MY (1) | MY204384A (enExample) |
| PE (1) | PE20210046A1 (enExample) |
| PL (1) | PL3762380T3 (enExample) |
| PT (1) | PT3762380T (enExample) |
| RS (1) | RS62833B1 (enExample) |
| SG (1) | SG11202008504SA (enExample) |
| SI (1) | SI3762380T1 (enExample) |
| SM (1) | SMT202200067T1 (enExample) |
| TW (1) | TWI804585B (enExample) |
| WO (1) | WO2019173182A1 (enExample) |
| ZA (1) | ZA202006115B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018005756A (es) * | 2015-11-24 | 2018-08-01 | Squibb Bristol Myers Co | Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. |
| EP3634956B1 (en) | 2017-06-09 | 2021-04-07 | Bristol-Myers Squibb Company | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| WO2018227058A1 (en) * | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| JP7183193B2 (ja) | 2017-06-09 | 2022-12-05 | ブリストル－マイヤーズ スクイブ カンパニー | ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
| KR102615098B1 (ko) | 2017-06-09 | 2023-12-18 | 브리스톨-마이어스 스큅 컴퍼니 | 시클로프로필 우레아 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| AU2019232704B2 (en) | 2018-03-05 | 2024-03-21 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| KR102656571B1 (ko) | 2018-03-05 | 2024-04-11 | 아르커스 바이오사이언시즈 인코포레이티드 | 아르기나아제 억제제 |
| KR102877973B1 (ko) | 2018-11-26 | 2025-10-30 | 브리스톨-마이어스 스큅 컴퍼니 | 포르밀 펩티드 2 수용체 효능제로서의 피롤리디논 유도체 |
| CN114008059B (zh) * | 2019-06-18 | 2024-03-12 | 百时美施贵宝公司 | 联芳基二烷基氧化膦fpr2激动剂 |
| WO2022011084A1 (en) * | 2020-07-09 | 2022-01-13 | Bristol-Myers Squibb Company | Oxopyrrolidine fpr2 agonists |
| TW202216669A (zh) | 2020-07-09 | 2022-05-01 | 美商必治妥美雅史谷比公司 | 吡唑啉酮甲醯基肽2受體促效劑 |
| JP7802765B2 (ja) * | 2020-08-12 | 2026-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン尿素ｆｐｒ２アゴニスト |
| WO2022155859A1 (en) * | 2021-01-21 | 2022-07-28 | Beijing Tiantan Hospital | Modulators of fpr1 and methods of using the same |
| US20240300973A1 (en) * | 2021-01-21 | 2024-09-12 | Biofront Therapeutics (Beijing) Co., Ltd. | Modulators of fpr1 and methods of using the same |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| CN118401112A (zh) | 2021-12-15 | 2024-07-26 | 安道麦阿甘有限公司 | 用于制备各种农用化学品的化合物及其标记 |
| US20250205164A1 (en) | 2022-05-27 | 2025-06-26 | Asahi Group Holdings, Ltd. | Fpr2 agonist containing outer membrane vesicles derived from lactic acid bacterium |
| EP4602049A1 (en) | 2022-10-13 | 2025-08-20 | Bayer Aktiengesellschaft | Sos1 inhibitors |
| WO2024220487A1 (en) * | 2023-04-18 | 2024-10-24 | Bristol-Myers Squibb Company | Carbocyclic phenylpyrrolidinone urea fpr2 agonists |
| CN121013837A (zh) * | 2023-04-18 | 2025-11-25 | 百时美施贵宝公司 | 吡咯烷酮脲fpr2激动剂 |
| EP4698516A1 (en) * | 2023-04-18 | 2026-02-25 | Bristol-Myers Squibb Company | Pyrrolidinone urea fpr2 agonists |
| WO2025202955A1 (en) | 2024-03-28 | 2025-10-02 | Pi Industries Ltd. | Fused bicyclic compounds and their use as pest control agents |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202344A (en) | 1990-12-11 | 1993-04-13 | G. D. Searle & Co. | N-substituted lactams useful as cholecystokinin antagonists |
| EP0763020A1 (en) | 1994-06-02 | 1997-03-19 | Zeneca Limited | Substituted pyrrolidone, thiazolidones or oxazolidones as herbicides |
| TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| TWI354664B (en) * | 2003-08-21 | 2011-12-21 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine rece |
| KR20060130064A (ko) | 2003-11-07 | 2006-12-18 | 아카디아 파마슈티칼스 인코포레이티드 | 통증 및 염증 치료에 효과적인 화합물을 동정하기 위한도구로서의 리폭신 수용체, ｆｐｒｌ1의 용도 |
| WO2006063293A2 (en) | 2004-12-07 | 2006-06-15 | Portola Pharmaceuticals, Inc. | THIOUREAS AS FACTOR Xa INHIBITORS |
| US7678913B2 (en) | 2004-12-07 | 2010-03-16 | Portola Pharmaceuticals, Inc. | Ureas as factor Xa inhibitors |
| US20070123508A1 (en) | 2005-05-27 | 2007-05-31 | Roger Olsson | PAR2-modulating compounds and their use |
| AU2006265835B2 (en) | 2005-06-30 | 2012-05-03 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
| TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
| MX2010006241A (es) | 2007-12-18 | 2010-06-30 | Actelion Pharmaceuticals Ltd | Derivados de aminotriazol como agonistas de alx. |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| JP5580741B2 (ja) | 2008-09-19 | 2014-08-27 | 武田薬品工業株式会社 | 含窒素複素環化合物およびその用途 |
| WO2010094678A1 (en) | 2009-02-23 | 2010-08-26 | F. Hoffmann-La Roche Ag | Novel ortho-aminoamides for the treatment of cancer |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| KR20120046159A (ko) | 2009-06-12 | 2012-05-09 | 액테리온 파마슈티칼 리미티드 | Ａｌｘ 수용체 아고니스트로서의 옥사졸 및 티아졸 유도체 |
| CA2803920A1 (en) | 2010-06-24 | 2011-12-29 | Richard Beard | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| WO2012066488A2 (en) | 2010-11-17 | 2012-05-24 | Actelion Pharmaceuticals Ltd | Bridged spiro[2.4]heptane ester derivatives |
| CA2819457A1 (en) | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| US9346793B2 (en) | 2010-12-07 | 2016-05-24 | Actelion Pharmaceuticals, Ltd. | Hydroxylated aminotriazole derivatives as ALX receptor agonists |
| HRP20150049T1 (hr) | 2010-12-07 | 2015-02-27 | Actelion Pharmaceuticals Ltd. | Derivati oksazolil-metiletera kao agonisti alx-receptora |
| CA2827005A1 (en) | 2011-02-11 | 2012-08-16 | Allergan, Inc. | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators |
| US8653299B2 (en) | 2011-03-17 | 2014-02-18 | Allergan, Inc. | Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| MY173181A (en) | 2011-05-13 | 2020-01-02 | Array Biopharma Inc | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors |
| JP5982001B2 (ja) | 2011-10-26 | 2016-08-31 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのｎ−尿素置換アミノ酸のアミド誘導体 |
| US8541577B2 (en) | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| NZ700733A (en) | 2012-04-16 | 2016-07-29 | Allergan Inc | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| EP2922844B1 (en) | 2012-11-13 | 2018-01-10 | Array Biopharma, Inc. | N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2015009545A1 (en) | 2013-07-16 | 2015-01-22 | Allergan, Inc. | Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| NZ720508A (en) | 2013-11-28 | 2019-03-29 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof |
| HUE049827T2 (hu) | 2013-12-03 | 2020-10-28 | Fmc Corp | Pirrolidinonok mint herbicidek |
| LT3154959T (lt) | 2014-05-15 | 2019-09-25 | Array Biopharma, Inc. | 1-((3s,4r)-4-(3-fluorfenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)karbamidas kaip trka kinazės inhibitorius |
| AU2016210544B2 (en) | 2015-01-23 | 2020-12-10 | Gvk Biosciences Private Limited | Inhibitors of TrkA kinase |
| EP3303284B1 (en) | 2015-05-27 | 2020-04-08 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| EA201792382A1 (ru) | 2015-05-27 | 2018-04-30 | Киорин Фармасютикал Ко., Лтд. | Производное мочевины или его фармакологически приемлемая соль |
| MX2018005756A (es) | 2015-11-24 | 2018-08-01 | Squibb Bristol Myers Co | Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. |
| EA034227B1 (ru) | 2015-12-10 | 2020-01-20 | Бристол-Майерс Сквибб Компани | Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1 |
| US10851053B2 (en) | 2016-06-08 | 2020-12-01 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| WO2018227058A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| KR102615098B1 (ko) | 2017-06-09 | 2023-12-18 | 브리스톨-마이어스 스큅 컴퍼니 | 시클로프로필 우레아 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| EP3634956B1 (en) | 2017-06-09 | 2021-04-07 | Bristol-Myers Squibb Company | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| JP7183193B2 (ja) | 2017-06-09 | 2022-12-05 | ブリストル－マイヤーズ スクイブ カンパニー | ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
| AU2019232704B2 (en) | 2018-03-05 | 2024-03-21 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
-
2019
- 2019-03-04 AU AU2019232704A patent/AU2019232704B2/en active Active
- 2019-03-04 SM SM20220067T patent/SMT202200067T1/it unknown
- 2019-03-04 IL IL277044A patent/IL277044B2/en unknown
- 2019-03-04 MY MYPI2020004526A patent/MY204384A/en unknown
- 2019-03-04 CA CA3092927A patent/CA3092927A1/en active Pending
- 2019-03-04 BR BR112020017744-0A patent/BR112020017744A2/pt unknown
- 2019-03-04 EP EP19711769.0A patent/EP3762380B1/en active Active
- 2019-03-04 RS RS20220063A patent/RS62833B1/sr unknown
- 2019-03-04 CN CN201980017438.1A patent/CN111868052B/zh active Active
- 2019-03-04 PT PT197117690T patent/PT3762380T/pt unknown
- 2019-03-04 EA EA202092094A patent/EA202092094A1/ru unknown
- 2019-03-04 MX MX2020009000A patent/MX2020009000A/es unknown
- 2019-03-04 HR HRP20220118TT patent/HRP20220118T1/hr unknown
- 2019-03-04 TW TW108107094A patent/TWI804585B/zh active
- 2019-03-04 HU HUE19711769A patent/HUE058044T2/hu unknown
- 2019-03-04 PL PL19711769T patent/PL3762380T3/pl unknown
- 2019-03-04 DK DK19711769.0T patent/DK3762380T3/da active
- 2019-03-04 PE PE2020001309A patent/PE20210046A1/es unknown
- 2019-03-04 KR KR1020207028222A patent/KR102803660B1/ko active Active
- 2019-03-04 SI SI201930151T patent/SI3762380T1/sl unknown
- 2019-03-04 US US16/291,209 patent/US10676431B2/en active Active
- 2019-03-04 SG SG11202008504SA patent/SG11202008504SA/en unknown
- 2019-03-04 ES ES19711769T patent/ES2904483T3/es active Active
- 2019-03-04 JP JP2020546499A patent/JP7155276B2/ja active Active
- 2019-03-04 EP EP21207176.5A patent/EP3981767B1/en active Active
- 2019-03-04 WO PCT/US2019/020493 patent/WO2019173182A1/en not_active Ceased
- 2019-03-04 LT LTEPPCT/US2019/020493T patent/LT3762380T/lt unknown
- 2019-03-06 AR ARP190100548A patent/AR114429A1/es unknown
-
2020
- 2020-04-24 US US16/858,319 patent/US11117861B2/en active Active
- 2020-08-28 CL CL2020002224A patent/CL2020002224A1/es unknown
- 2020-10-02 ZA ZA2020/06115A patent/ZA202006115B/en unknown
-
2021
- 2021-08-12 US US17/400,421 patent/US11708327B2/en active Active
-
2022
- 2022-02-11 CY CY20221100123T patent/CY1124985T1/el unknown